Probable interaction between tolterodine and warfarin

Pharmacotherapy

Volumn 26, Issue 5 I, 2006, Pages 719-721

  Taylor, James R ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Drug interactions; Tolterodine; Warfarin

Indexed keywords

TOLTERODINE; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; OVERACTIVE BLADDER; PRESCRIPTION; THROMBOEMBOLISM;

EID: 33646381604     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.5.719     Document Type: Article

References (10)

1. Liberman JN, Hunt TL, Stewarta WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50.
2. Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001;19:141-7.
3. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
4. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;33:1173-6.
5. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin k antagonists. Chest 2004;126(suppl 3):S204-33.
6. Erdman SM, Rodvold KA, Friedenburg WR. Thromboembolic disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 3rd ed. Stamford, CT: Appleton & Lange, 1996:399-433.
7. Yacobi A, Udall JA, Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976;19:552-8.
8. Pharmacia & Upjohn Co. Detrol (tolterodine tartrate) product monograph. Kalamazoo, MI; 1998.
9. Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung 2002;52:890-5.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.